Guggenheim Maintains Buy on Monte Rosa Therapeutics, Lowers Price Target to $28

Benzinga · 1d ago
Guggenheim analyst Michael Schmidt maintains Monte Rosa Therapeutics (NASDAQ:GLUE) with a Buy and lowers the price target from $35 to $28.